Chronic idiopathic constipation is a highly prevalent functional bowel disorder that affects millions of individuals worldwide. Some of the major factors that contribute to the burgeoning number of patients suffering from chronic idiopathic constipation include sedentary lifestyle, increasing usage of anti-inflammatory agents, and drastic decline in the intake of dietary fibers. Over the past few years, considerable efforts have been made to improve the management of chronic idiopathic constipation. In the current scenario, empiric therapy has garnered considerable attention from the stakeholders operating in the current chronic idiopathic constipation treatment market – a trend that is expected to continue during the forecast period.
Researchers involved in the current chronic idiopathic constipation treatment market landscape are also increasingly focusing on the development of customized treatment plans that offer multi-symptom relief. Efforts are being made to improve the efficacy of the current therapeutic agents due to which, a steady growth of the global chronic idiopathic constipation treatment market is anticipated in the upcoming years. A number of players involved in the current market for chronic idiopathic constipation treatment are focusing on gaining approval from the FDA for the newly developed drugs and treatments.
At the back of these factors, along with the augmenting demand for chronic idiopathic constipation treatment, the global chronic idiopathic constipation treatment market is expected to surpass the US$ 15.9 Bn mark by the end of 2030.
In the initial stages, chronic idiopathic constipation treatment primarily included a blend of medication review, lifestyle modifications, and patient education. While prescription treatments are expected to witness considerable adoption worldwide, a number of non-prescription chronic idiopathic constipation treatments, including fiber supplementation, has garnered popularity. Moreover, research activities suggest that soluble fibers such as psyllium offer relief to patients suffering from chronic idiopathic constipation in comparison with insoluble fibers including bran. The increasing usage of soluble fibers has led to a noteworthy improvement in global symptoms and stool consistency due to which, the chronic idiopathic constipation treatment market is largely leaning toward the utilization of soluble fibers in the empiric fiber therapy. The rising usage of osmotic laxatives, stimulant laxative, and bulking laxatives is expected to contribute to the growth of the global chronic idiopathic constipation treatment market as the demand for non-prescription treatments continues to move in the upward trajectory.
While non-prescription treatments are gradually gaining worldwide adoption, the demand for prescription treatments is on the rise. However, players operating in the current chronic idiopathic constipation treatment market landscape are increasingly focusing on catering to the unmet needs with existing chronic idiopathic constipation treatment alternatives.
Unpredictability, poor symptom relief, bloating, and inability to enhance the quality of life of current treatments have compelled companies in the current market for chronic idiopathic constipation treatment to introduce better prescription agents and mechanisms. Some of the recently developed prescription agents that are gaining fast-paced adoption include prosecretory agents and a host of FDA approved products such as linaclotide.
In the current scenario, manufacturers operating in the chronic idiopathic constipation treatment market are increasingly seeking the approval of the FDA for their newly developed drugs. Gaining the approval of the FDA is expected to remain one of the core areas of focus for the chronic idiopathic constipation drug manufacturers over the course of the forecast period. A number of drugs has received the green signal from the FDA in recent years.
In February 2020, the U.S. FDA approved an osmotic laxative developed by the Braintree Laboratories to treat chronic idiopathic constipation among adults. While attaining the FDA approval is expected to remain a top priority, market players are likely to increase the R&D spending on the development of new therapeutics and products.
The onset of the COVID-19 pandemic is expected to have a moderate impact on the global chronic idiopathic constipation treatment market in 2020. The first quarter of 2020 witnessed steady ascension in the demand for chronic idiopathic constipation treatment worldwide. However, outbreak of the COVID-19 pandemic toward the end of the first quarter and stringent lockdown measures implemented by governments in the second and the third quarter of 2020 are expected to negatively affect the adoption of chronic idiopathic constipation treatment. However, the demand is set to witness considerable growth toward the end of 2020, as governments around the world continue to lift the lockdown measures in a phased manner.
Analysts’ Viewpoint
The global chronic idiopathic constipation treatment market is expected to grow at a healthy CAGR of ~7% during the forecast period. The market growth can be primarily attributed to factors such as increasing prevalence of chronic idiopathic constipation among adults worldwide, high demand for improved chronic idiopathic constipation treatment and therapies to address unmet needs of existing treatments, and research and development activities. Market players should focus on the development of new prescription as well as non-prescription chronic idiopathic constipation treatments and continue to invest in R&D activities.
Chronic Idiopathic Constipation Treatment Market to surpass valuation of US$ 15.9 Bn by 2030
Chronic Idiopathic Constipation Treatment Market is projected to expand at a CAGR of ~7% from 2020 to 2030
Chronic Idiopathic Constipation Treatment Market is driven by increase in R&D activities and expenditure on new products and therapeutics development
North America accounted for major share of the global chronic idiopathic constipation treatment market and the trend is anticipated to continue during the forecast period
Key players in the global chronic idiopathic constipation treatment market include Bayer AG, Allergan, Bausch Health, Sanofi, Takeda Pharmaceutical Company
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Chronic Idiopathic Constipation Treatment Market
4. Market Overview
4.1. Introduction
4.1.1. Drug Class Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Chronic Idiopathic Constipation Treatment Market Analysis and Forecast, 2018–2030
5. Key Insights
5.1. Pipeline Analysis
5.2. COVID-19 Pandemic Impact on Industry (Value Chain and Short / Mid / Long Term Impact)
5.3. Diseases Prevalence by Global/Sub-region
5.4. Key Developments
6. Global Chronic Idiopathic Constipation Treatment Market Analysis and Forecast, by Drug Class
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Global Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2018–2030
6.3.1. Serotonin-4 (5-Ht4) Receptor Agonist
6.3.1.1. Prucalopride
6.3.1.2. Others
6.3.2. Guanylate Cyclase-C Agonist
6.3.2.1. Plecanatide
6.3.2.2. Linaclotide
6.3.3. Laxatives
6.3.3.1. Sodium Picosulphate
6.3.3.2. Polycarbophil
6.3.3.3. Others
6.3.4. Stimulants
6.3.4.1. Bisacodyl
6.3.4.2. Senokot
6.3.4.3. Others
6.3.5. Others
6.4. Global Chronic Idiopathic Constipation Treatment Market Attractiveness, by Drug Class
7. Global Chronic Idiopathic Constipation Treatment Market Analysis and Forecast, by Route of Administration
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Global Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2018–2030
7.3.1. Oral
7.3.2. Rectal
7.4. Global Chronic Idiopathic Constipation Treatment Market Attractiveness, by Route of Administration
8. Global Chronic Idiopathic Constipation Treatment Market Analysis and Forecast, by Distribution Channel
8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Global Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030
8.3.1. Hospital Pharmacies
8.3.2. Retail Pharmacies
8.3.3. Online Pharmacies
8.4. Global Chronic Idiopathic Constipation Treatment Market Attractiveness, by Distribution Channel
9. Global Chronic Idiopathic Constipation Treatment Market Analysis and Forecast, by Region
9.1. Key Findings
9.2. Global Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Region
9.2.1. North America
9.2.2. Europe
9.2.3. Asia Pacific
9.2.4. Latin America
9.2.5. Middle East & Africa
9.3. Global Chronic Idiopathic Constipation Treatment Market Attractiveness, by Region
10. North America Chronic Idiopathic Constipation Treatment Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. North America Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2018–2030
10.2.1. Serotonin-4 (5-Ht4) Receptor Agonist
10.2.1.1. Prucalopride
10.2.1.2. Others
10.2.2. Guanylate Cyclase-C Agonist
10.2.2.1. Plecanatide
10.2.2.2. Linaclotide
10.2.3. Laxatives
10.2.3.1. Sodium Picosulphate
10.2.3.2. Polycarbophil
10.2.3.3. Others
10.2.4. Stimulants
10.2.4.1. Bisacodyl
10.2.4.2. Senokot
10.2.4.3. Others
10.2.5. Others
10.3. North America Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2018–2030
10.3.1. Oral
10.3.2. Rectal
10.4. North America Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030
10.4.1. Hospital Pharmacies
10.4.2. Retail Pharmacies
10.4.3. Online Pharmacies
10.5. North America Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Country, 2018–2030
10.5.1. U.S.
10.5.2. Canada
10.6. North America Chronic Idiopathic Constipation Treatment Market Attractiveness Analysis
10.6.1. By Drug Class
10.6.2. By Route of Administration
10.6.3. By Distribution Channel
10.6.4. By Country
11. Europe Chronic Idiopathic Constipation Treatment Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Europe Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2018–2030
11.2.1. Serotonin-4 (5-Ht4) Receptor Agonist
11.2.1.1. Prucalopride
11.2.1.2. Others
11.2.2. Guanylate Cyclase-C Agonist
11.2.2.1. Plecanatide
11.2.2.2. Linaclotide
11.2.3. Laxatives
11.2.3.1. Sodium Picosulphate
11.2.3.2. Polycarbophil
11.2.3.3. Others
11.2.4. Stimulants
11.2.4.1. Bisacodyl
11.2.4.2. Senokot
11.2.4.3. Others
11.2.5. Others
11.3. Europe Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2018–2030
11.3.1. Oral
11.3.2. Rectal
11.4. Europe Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030
11.4.1. Hospital Pharmacies
11.4.2. Retail Pharmacies
11.4.3. Online Pharmacies
11.5. Europe Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018–2030
11.5.1. Germany
11.5.2. U.K.
11.5.3. France
11.5.4. Spain
11.5.5. Italy
11.5.6. Rest of Europe
11.6. Europe Chronic Idiopathic Constipation Treatment Market Attractiveness Analysis
11.6.1. By Drug Class
11.6.2. By Route of Administration
11.6.3. By Distribution Channel
11.6.4. By Country/Sub-region
12. Asia Pacific Chronic Idiopathic Constipation Treatment Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Asia Pacific Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2018–2030
12.2.1. Serotonin-4 (5-Ht4) Receptor Agonist
12.2.1.1. Prucalopride
12.2.1.2. Others
12.2.2. Guanylate Cyclase-C Agonist
12.2.2.1. Plecanatide
12.2.2.2. Linaclotide
12.2.3. Laxatives
12.2.3.1. Sodium Picosulphate
12.2.3.2. Polycarbophil
12.2.3.3. Others
12.2.4. Stimulants
12.2.4.1. Bisacodyl
12.2.4.2. Senokot
12.2.4.3. Others
12.2.5. Others
12.3. Asia Pacific Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2018–2030
12.3.1. Oral
12.3.2. Rectal
12.4. Asia Pacific Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030
12.4.1. Hospital Pharmacies
12.4.2. Retail Pharmacies
12.4.3. Online Pharmacies
12.5. Asia Pacific Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018–2030
12.5.1. China
12.5.2. Japan
12.5.3. India
12.5.4. Australia & New Zealand
12.5.5. Rest of Asia Pacific
12.6. Asia Pacific Chronic Idiopathic Constipation Treatment Market Attractiveness Analysis
12.6.1. By Drug Class
12.6.2. By Route of Administration
12.6.3. By Distribution Channel
12.6.4. By Country/Sub-region
13. Latin America Chronic Idiopathic Constipation Treatment Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Latin America Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2018–2030
13.2.1. Serotonin-4 (5-Ht4) Receptor Agonist
13.2.1.1. Prucalopride
13.2.1.2. Others
13.2.2. Guanylate Cyclase-C Agonist
13.2.2.1. Plecanatide
13.2.2.2. Linaclotide
13.2.3. Laxatives
13.2.3.1. Sodium Picosulphate
13.2.3.2. Polycarbophil
13.2.3.3. Others
13.2.4. Stimulants
13.2.4.1. Bisacodyl
13.2.4.2. Senokot
13.2.4.3. Others
13.2.5. Others
13.3. Latin America Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2018–2030
13.3.1. Oral
13.3.2. Rectal
13.4. Latin America Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030
13.4.1. Hospital Pharmacies
13.4.2. Retail Pharmacies
13.4.3. Online Pharmacies
13.5. Latin America Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018–2030
13.5.1. Brazil
13.5.2. Mexico
13.5.3. Rest of Latin America
13.6. Latin America Chronic Idiopathic Constipation Treatment Market Attractiveness Analysis
13.6.1. By Drug Class
13.6.2. By Route of Administration
13.6.3. By Distribution Channel
13.6.4. By Country/Sub-region
14. Middle East & Africa Chronic Idiopathic Constipation Treatment Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Middle East & Africa Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2018–2030
14.2.1. Serotonin-4 (5-Ht4) Receptor Agonist
14.2.1.1. Prucalopride
14.2.1.2. Others
14.2.2. Guanylate Cyclase-C Agonist
14.2.2.1. Plecanatide
14.2.2.2. Linaclotide
14.2.3. Laxatives
14.2.3.1. Sodium Picosulphate
14.2.3.2. Polycarbophil
14.2.3.3. Others
14.2.4. Stimulants
14.2.4.1. Bisacodyl
14.2.4.2. Senokot
14.2.4.3. Others
14.2.5. Others
14.3. Middle East & Africa Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2018–2030
14.3.1. Oral
14.3.2. Rectal
14.4. Middle East & Africa Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030
14.4.1. Hospital Pharmacies
14.4.2. Retail Pharmacies
14.4.3. Online Pharmacies
14.5. Middle East & Africa Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018–2030
14.5.1. GCC Countries
14.5.2. South Africa
14.5.3. Rest of Middle East & Africa
14.6. Middle East & Africa Chronic Idiopathic Constipation Treatment Market Attractiveness Analysis
14.6.1. By Drug Class
14.6.2. By Route of Administration
14.6.3. By Distribution Channel
14.6.4. By Country/Sub-region
15. Competition Landscape
15.1. Market Player – Competition Matrix (By Tier and Size of companies)
15.2. Market Share Analysis/Ranking By Company (2019)
15.3. Company Profiles
15.3.1. Bayer AG
15.3.1.1. Company Overview
15.3.1.2. Company Financials
15.3.1.3. Growth Strategies
15.3.1.4. SWOT Analysis
15.3.2. Allergan
15.3.2.1. Company Overview
15.3.2.2. Company Financials
15.3.2.3. Growth Strategies
15.3.2.4. SWOT Analysis
15.3.3. Bausch Health
15.3.3.1. Company Overview
15.3.3.2. Company Financials
15.3.3.3. Growth Strategies
15.3.3.4. SWOT Analysis
15.3.4. Sanofi
15.3.4.1. Company Overview
15.3.4.2. Company Financials
15.3.4.3. Growth Strategies
15.3.4.4. SWOT Analysis
15.3.5. Takeda Pharmaceutical Company
15.3.5.1. Company Overview
15.3.5.2. Company Financials
15.3.5.3. Growth Strategies
15.3.5.4. SWOT Analysis
15.3.6. SEBELA PHARMACEUTICALS
15.3.6.1. Company Overview
15.3.6.2. Growth Strategies
15.3.6.3. SWOT Analysis
15.3.7. Ironwood Pharmaceuticals, Inc.
15.3.7.1. Company Overview
15.3.7.2. Company Financials
15.3.7.3. Growth Strategies
15.3.7.4. SWOT Analysis
15.3.8. Albireo Pharma, Inc.
15.3.8.1. Company Overview
15.3.8.2. Company Financials
15.3.8.3. Growth Strategies
15.3.8.4. SWOT Analysis
15.3.9. Sucampo Pharmaceuticals, Inc. (Mallinckrodt)
15.3.9.1. Company Overview
15.3.9.2. Company Financials
15.3.9.3. Growth Strategies
15.3.9.4. SWOT Analysis
15.3.10. Janssen Pharmaceuticals, Inc. (Johnson & Johnson)
15.3.10.1. Company Overview
15.3.10.2. Company Financials
15.3.10.3. Growth Strategies
15.3.10.4. SWOT Analysis
List of Tables
Table 01: Global Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2018–2030
Table 02: Global Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Serotonin-4 (5-Ht4) Receptor Agonist, 2018–2030
Table 03: Global Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Guanylate Cyclase-C Agonist, 2018–2030
Table 04: Global Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Laxatives, 2018–2030
Table 05: Global Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Stimulants, 2018–2030
Table 06: Global Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2018–2030
Table 07: Global Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030
Table 08: Global Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Region, 2018–2030
Table 09: North America Chronic Idiopathic Constipation Market Value (US$ Mn) Forecast, by Country, 2018–2030
Table 10: North America Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2018–2030
Table 11: North America Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Serotonin-4 (5-Ht4) Receptor Agonist, 2018–2030
Table 12: North America Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Guanylate Cyclase-C Agonist, 2018–2030
Table 13: North America Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Laxatives, 2018–2030
Table 14: North America Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Stimulants, 2018–2030
Table 15: North America Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2018–2030
Table 16: North America Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030
Table 17: Europe Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018–2030
Table 18: Europe Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2018–2030
Table 19: Europe Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Serotonin-4 (5-Ht4) Receptor Agonist, 2018–2030
Table 20: North America Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Guanylate Cyclase-C Agonist, 2018–2030
Table 21: Europe Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Laxatives, 2018–2030
Table 22: Europe Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Stimulants, 2018–2030
Table 23: Europe Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2018–2030
Table 24: Europe Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030
Table 25: Asia Pacific Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018–2030
Table 26: Asia Pacific Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2018–2030
Table 27: Asia Pacific Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Serotonin-4 (5-Ht4) Receptor Agonist, 2018–2030
Table 28: Asia Pacific Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Guanylate Cyclase-C Agonist, 2018–2030
Table 29: Asia Pacific Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Laxatives, 2018–2030
Table 30: Asia Pacific Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Stimulants, 2018–2030
Table 31: Asia Pacific Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2018–2030
Table 32: Asia Pacific Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030
Table 33: Latin America Chronic Idiopathic Constipation Market Value (US$ Mn) Forecast, by Country, 2018–2030
Table 34: Latin America Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2018–2030
Table 35: Latin America Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Serotonin-4 (5-Ht4) Receptor Agonist, 2018–2030
Table 36: Latin America Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Guanylate Cyclase-C Agonist, 2018–2030
Table 37: Latin America Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Laxatives, 2018–2030
Table 38: Latin America Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Stimulants, 2018–2030
Table 39: Latin America Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2018–2030
Table 40: North America Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030
Table 41: Middle East & Africa Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018–2030
Table 42: Middle East & Africa Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2018–2030
Table 43: Middle East & Africa Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Serotonin-4 (5-Ht4) Receptor Agonist, 2018–2030
Table 44: Middle East & Africa Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Guanylate Cyclase-C Agonist, 2018–2030
Table 45: Middle East & Africa Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Laxatives, 2018–2030
Table 46: Middle East & Africa Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Stimulants, 2018–2030
Table 47: Middle East & Africa Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2018–2030
Table 48: Middle East & Africa Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030
List of Figures
Figure 01: Global Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, 2018–2030
Figure 02: Global Chronic Idiopathic Constipation Treatment Market Value Share, by Drug Class, 2019
Figure 03: Global Chronic Idiopathic Constipation Treatment Market Value Share, by Route of Administration, 2019
Figure 04: Global Chronic Idiopathic Constipation Treatment Market Value Share, by Distribution Channel, 2019
Figure 05: Global Chronic Idiopathic Constipation Treatment Market Value Share, by Region, 2019
Figure 06: Global Chronic Idiopathic Constipation Treatment Market Value Share Analysis, by Drug Class, 2019 and 2030
Figure 07: Global Chronic Idiopathic Constipation Treatment Market Attractiveness Analysis, by Drug Class, 2020–2030
Figure 08: Global Chronic Idiopathic Constipation Treatment Market Value (US$ Mn), by Serotonin-4 (5-Ht4) Receptor Agonist, 2018–2030
Figure 09: Global Chronic Idiopathic Constipation Treatment Market Value (US$ Mn), by Guanylate Cyclase-C Agonist, 2018–2030
Figure 10: Global Chronic Idiopathic Constipation Treatment Market Value (US$ Mn), by Laxatives, 2018–2030
Figure 11: Global Chronic Idiopathic Constipation Treatment Market Value (US$ Mn), by Stimulants, 2018–2030
Figure 12: Global Chronic Idiopathic Constipation Treatment Market Value (US$ Mn), by Others, 2018–2030
Figure 13: Global Chronic Idiopathic Constipation Treatment Market Value Share Analysis, by Serotonin-4 (5-Ht4) Receptor Agonist, 2019 and 2030
Figure 14: Global Chronic Idiopathic Constipation Treatment Market Attractiveness Analysis, by Serotonin-4 (5-Ht4) Receptor Agonist, 2020–2030
Figure 15: Global Chronic Idiopathic Constipation Treatment Market Value Share Analysis, by Guanylate Cyclase-C Agonist, 2019 and 2030
Figure 16: Global Chronic Idiopathic Constipation Treatment Market Attractiveness Analysis, by Guanylate Cyclase-C Agonist, 2020–2030
Figure 17: Global Chronic Idiopathic Constipation Treatment Market Value Share Analysis, by Laxatives, 2019 and 2030
Figure 18: Global Chronic Idiopathic Constipation Treatment Market Attractiveness Analysis, by Laxatives, 2020–2030
Figure 19: Global Chronic Idiopathic Constipation Treatment Market Value Share Analysis, by Stimulants, 2019 and 2030
Figure 20: Global Chronic Idiopathic Constipation Treatment Market Attractiveness Analysis, by Stimulants, 2020–2030
Figure 21: Global Chronic Idiopathic Constipation Treatment Market Value Share Analysis, by Route of Administration, 2019 and 2030
Figure 22: Global Chronic Idiopathic Constipation Treatment Market Attractiveness Analysis, by Route of Administration, 2020–2030
Figure 23: Global Chronic Idiopathic Constipation Treatment Market Value (US$ Mn), by Oral, 2018–2030
Figure 24: Global Chronic Idiopathic Constipation Treatment Market Value (US$ Mn), by Rectal, 2018–2030
Figure 25: Global Chronic Idiopathic Constipation Treatment Market Value Share Analysis, by Distribution Channel, 2019 and 2030
Figure 26: Global Chronic Idiopathic Constipation Treatment Market Attractiveness Analysis, by Distribution Channel, 2020–2030
Figure 27: Global Chronic Idiopathic Constipation Treatment Market Value (US$ Mn), by Hospital Pharmacies, 2018–2030
Figure 28: Global Chronic Idiopathic Constipation Treatment Market Value (US$ Mn), by Retail Pharmacies, 2018–2030
Figure 29: Global Chronic Idiopathic Constipation Treatment Market Value (US$ Mn), by Online Pharmacies, 2018–2030
Figure 30: Global Chronic Idiopathic Constipation Treatment Market Value Share Analysis, by Region, 2019 and 2030
Figure 31: Global Chronic Idiopathic Constipation Treatment Market Attractiveness Analysis, by Region
Figure 32: North America Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018–2030
Figure 33: North America Chronic Idiopathic Constipation Market Value Share (%), by Country, 2019 and 2030
Figure 34: North America Chronic Idiopathic Constipation Market Attractiveness, by Country, 2020–2030
Figure 35: North America Chronic Idiopathic Constipation Treatment Market Value Share (%), by Drug Class, 2019 and 2030
Figure 36: North America Chronic Idiopathic Constipation Treatment Market Attractiveness, by Drug Class, 2020–2030
Figure 37: North America Chronic Idiopathic Constipation Treatment Market Value Share (%), by Route of Administration, 2019 and 2030
Figure 38: North America Chronic Idiopathic Constipation Treatment Market Attractiveness, by Route of Administration, 2020–2030
Figure 39: North America Chronic Idiopathic Constipation Treatment Market Value Share (%), by Distribution Channel, 2019 and 2030
Figure 40: North America Chronic Idiopathic Constipation Treatment Market Attractiveness, by Distribution Channel, 2020–2030
Figure 41: Europe Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018–2030
Figure 42: Europe Chronic Idiopathic Constipation Treatment Market Value Share (%), by Country/Sub-region, 2019 and 2030
Figure 43: Europe Chronic Idiopathic Constipation Treatment Market Attractiveness, by Country/Sub-region, 2020–2030
Figure 44: Europe Chronic Idiopathic Constipation Treatment Market Value Share (%), by Drug Class, 2019 and 2030
Figure 45: Europe Chronic Idiopathic Constipation Treatment Market Attractiveness, by Drug Class, 2020–2030
Figure 46: Europe Chronic Idiopathic Constipation Treatment Market Value Share (%), by Route of Administration, 2019 and 2030
Figure 47: Europe Chronic Idiopathic Constipation Treatment Market Attractiveness, by Route of Administration, 2020–2030
Figure 48: Europe Chronic Idiopathic Constipation Treatment Market Value Share (%), by Distribution Channel, 2019 and 2030
Figure 49: Europe Chronic Idiopathic Constipation Treatment Market Attractiveness, by Distribution Channel, 2020–2030
Figure 50: Asia Pacific Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018–2030
Figure 51: Asia Pacific Chronic Idiopathic Constipation Treatment Market Value Share (%), by Country/Sub-region, 2019 and 2030
Figure 52: Asia Pacific Chronic Idiopathic Constipation Treatment Market Attractiveness, by Country/Sub-region, 2020–2030
Figure 53: Asia Pacific Chronic Idiopathic Constipation Treatment Market Value Share (%), by Drug Class, 2019 and 2030
Figure 54: Asia Pacific Chronic Idiopathic Constipation Treatment Market Attractiveness, by Drug Class, 2020–2030
Figure 55: Asia Pacific Chronic Idiopathic Constipation Treatment Market Value Share (%), by Route of Administration, 2019 and 2030
Figure 56: Asia Pacific Chronic Idiopathic Constipation Treatment Market Attractiveness, by Route of Administration, 2020–2030
Figure 57: Asia Pacific Chronic Idiopathic Constipation Treatment Market Value Share (%), by Distribution Channel, 2019 and 2030
Figure 58: Asia Pacific Chronic Idiopathic Constipation Treatment Market Attractiveness, by Distribution Channel, 2020–2030
Figure 59: Latin America Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018–2030
Figure 60: Latin America Chronic Idiopathic Constipation Market Value Share (%), by Country/Sub-region, 2019 and 2030
Figure 61: Latin America Chronic Idiopathic Constipation Market Attractiveness, by Country/Sub-region, 2020–2030
Figure 62: Latin America Chronic Idiopathic Constipation Treatment Market Value Share (%), by Drug Class, 2019 and 2030
Figure 63: Latin America Chronic Idiopathic Constipation Treatment Market Attractiveness, by Drug Class, 2020–2030
Figure 64: Latin America Chronic Idiopathic Constipation Treatment Market Value Share (%), by Route of Administration, 2019 and 2030
Figure 65: Latin America Chronic Idiopathic Constipation Treatment Market Attractiveness, by Route of Administration, 2020–2030
Figure 66: Latin America Chronic Idiopathic Constipation Treatment Market Value Share (%), by Distribution Channel, 2019 and 2030
Figure 67: Latin America Chronic Idiopathic Constipation Treatment Market Attractiveness, by Distribution Channel, 2020–2030
Figure 68: Middle East & Africa Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018–2030
Figure 69: Middle East & Africa Chronic Idiopathic Constipation Treatment Market Value Share (%), by Country/Sub-region, 2019 and 2030
Figure 70: Middle East & Africa Chronic Idiopathic Constipation Treatment Market Attractiveness, by Country/Sub-region, 2020–2030
Figure 71: Middle East & Africa Chronic Idiopathic Constipation Treatment Market Value Share (%), by Drug Class, 2019 and 2030
Figure 72: Middle East & Africa Chronic Idiopathic Constipation Treatment Market Attractiveness, by Drug Class, 2020–2030
Figure 73: Middle East & Africa Chronic Idiopathic Constipation Treatment Market Value Share (%), by Route of Administration, 2019 and 2030
Figure 74: Middle East & Africa Chronic Idiopathic Constipation Treatment Market Attractiveness, by Route of Administration, 2020–2030
Figure 75: Middle East & Africa Chronic Idiopathic Constipation Treatment Market Value Share (%), by Distribution Channel, 2019 and 2030
Figure 76: Middle East & Africa Chronic Idiopathic Constipation Treatment Market Attractiveness, by Distribution Channel, 2020–2030
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Chronic Idiopathic Constipation Treatment Market
